Feda Azab
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 43
- Multiple Myeloma Research and Treatments 42
- Genetics 35
- Chronic Lymphocytic Leukemia Research 35
- Co-authors
- Abdel Kareem Azab (67 shared papers)Barbara Muz (25 shared papers)Pilar de la Puente (22 shared papers)Irene M. Ghobrial (54 shared papers)Aldo Maria Roccaro (47 shared papers)Antonio Sacco (48 shared papers)Patricia Maiso (30 shared papers)Hai T. Ngo (42 shared papers)
- Journals
- Blood (44 papers)Clinical Cancer Research (7 papers)Blood Cancer Journal (4 papers)Molecular Cancer Research (2 papers)Leukemia (2 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Feda Azab
81 papers receiving 5.5k citations
Feda Azab's Hit Papers
Peers
Comparison fields: 5 of 104
- Hematology 1.4k
- Genetics 766
- Cancer Research 951
- Oncology 672
- Molecular Biology 1.4k
Countries citing papers authored by Feda Azab
This map shows the geographic impact of Feda Azab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feda Azab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feda Azab more than expected).
Fields of papers citing papers by Feda Azab
This network shows the impact of papers produced by Feda Azab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feda Azab. The network helps show where Feda Azab may publish in the future.
Co-authors
The 25 scholars most cited alongside Feda Azab, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 84 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy Hit paper breakdown → | 2015 | 1656 |
| 2 | BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression Hit paper breakdown → | 2013 | 693 |
| 3 | 2009 | 370 | |
| 4 | 2009 | 271 | |
| 5 | 2012 | 267 | |
| 6 | 2012 | 135 | |
| 7 | 2009 | 128 | |
| 8 | 2015 | 121 | |
| 9 | 2011 | 107 | |
| 10 | 2010 | 104 | |
| 11 | 2008 | 101 | |
| 12 | 2009 | 99 | |
| 13 | 2008 | 98 | |
| 14 | 2013 | 98 | |
| 15 | 2008 | 94 | |
| 16 | 2010 | 93 | |
| 17 | 2009 | 85 | |
| 18 | 2010 | 73 | |
| 19 | 2008 | 70 | |
| 20 | 2011 | 70 |
About Feda Azab
Feda Azab is a scholar working on Hematology, Genetics, Cancer Research, Oncology and Molecular Biology, having authored 84 papers that have together received 5.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (42 papers), Chronic Lymphocytic Leukemia Research (35 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Chemokine receptors and signaling (4 papers), Cancer, Hypoxia, and Metabolism (2 papers), MicroRNA in disease regulation (2 papers), Extracellular vesicles in disease (2 papers) and Ubiquitin and proteasome pathways (2 papers). The work is most often cited by research in Hematology (1.4k citations), Genetics (766 citations), Cancer Research (951 citations), Oncology (672 citations) and Molecular Biology (1.4k citations). Feda Azab has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Abdel Kareem Azab, Barbara Muz, Pilar de la Puente, Irene M. Ghobrial, Aldo Maria Roccaro, Antonio Sacco, Patricia Maiso, Hai T. Ngo, Kenneth Carl Anderson and Judith M. Runnels. Their work appears in journals such as Blood, Clinical Cancer Research, Blood Cancer Journal, Molecular Cancer Research and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.